

## MYD88 L265P Mutation Detection Kit

- Precision Detection of MYD88 L265P Mutation
- Ultra-Sensitive Mutation Detection
- Advanced Real-Time PCR Technology
- Designed for Molecular Characterization
- Broad Instrument Compatibility
- Optimized Workflow for Molecular Laboratories

RUO

Real-time  
PCR



MULTIPLEX



FAST



SENSITIVE




QUANTITATIVE

### High-Sensitivity Real-Time PCR Assay for MYD88 Mutation Detection

The geneMAP™ MYD88 L265P Mutation Detection Kit is a highly sensitive Real-Time PCR assay developed for the qualitative detection of the MYD88 L265P mutation in genomic DNA isolated from human clinical samples.

This mutation is a well-recognized molecular marker in several B-cell lymphoproliferative disorders, particularly Waldenström Macroglobulinemia and certain subtypes of Diffuse Large B-Cell Lymphoma.

### Simple real time - PCR Workflow




Sample preparation



qPCR amplification

Multiplex qPCR using primers designed to amplify the DNA sequences specific to each mutation of interest



Data interpretation

Mutations are identified by allele-specific real time PCR.



### Validated PCR Instruments

- Bio-Rad CFX96
- Life Technologies ABI-7500, QuantStudio Series
- Roche, Light Cycler 480 II
- Qiagen Rotor-Gene® 3000 Q5/Q6
- BioMolecular Systems, MicPCR


### Ordering Information

MYD88-RT25  
geneMAP™ MYD88 L265P Mutation  
Detection Kit  
25 tests **RUO**

Available as RUO in all countries.

### Technical Specifications

For Detection of MYD88 L265P mutation.



CONTENTS	VOLUME
4x MYD88 (L265P) Wildtype PPM	125 µl
4x MYD88 (L265P) Mutant PPM	125 µl
2x Master Mix	550 µl
RNase Free Water	400 µl
Positive Control	50 µl

In GENMARK SAĞLIK URUNLERI, we aim to create the top quality, time and cost efficient, trust-worthy and user-friendly products. We specialize in in-vitro detection kit production and development which is used for the diagnosis and treatment monitoring of many diseases connected to genetics, oncology, microbiology and hematological oncology.